Research article

Gene expression and activity of cartilage degrading glycosidases in human rheumatoid arthritis and osteoarthritis synovial fibroblasts

Mária Pásztói1, György Nagy2, Pál Géher2, Tamás Lakatos2, Kálmán Tóth3, Károly Wellinger3, Péter Pócza1, Bence György1, Marianna C Holub1, Ágnes Kittel4, Krisztna Pálóczy1, Mercédesz Mazán1, Péter Nyirkos1, András Falus1,5 and Edit I Buzas1

1Department of Genetics, Cell and Immunobiology, Semmelweis University, Nagyvárad tér 4, Budapest H-1089, Hungary
2Department of Rheumatology, Semmelweis University, Frankel Leó utca 54, Budapest H-1027, Hungary
3Department of Orthopedic Surgery, Szeged University, Semmelweis u.6, Szeged H-6725, Hungary
4Institute of Experimental Medicine, Hungarian Academy of Sciences, Szigony u. 43, Budapest H-1083, Hungary
5Inflammation Biology and Immunogenomics Research Group, Hungarian Academy of Sciences-Semmelweis University, Nagyvárad tér 4, Budapest H-1089, Hungary

Corresponding author: Edit I Buzas, edit.buzas@gmail.com

Received: 14 Nov 2008 Revisions requested: 18 Dec 2008 Revisions received: 9 Mar 2009 Accepted: 14 May 2009 Published: 14 May 2009

Arthritis Research & Therapy 2009, 11:R68 (doi:10.1186/ar2697)

This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Introduction Similar to matrix metalloproteinases, glycosidases also play a major role in cartilage degradation. Carbohydrate cleavage products, generated by these latter enzymes, are released from degrading cartilage during arthritis. Some of the cleavage products (such as hyaluronic oligosaccharides) have been shown to bind to Toll-like receptors and provide endogenous danger signals, while others (like N-acetyl glucosamine) are reported to have chondroprotective functions. In the current study for the first time we systematically investigated the expression of glycosidases within the joints.

Methods Expressions of β-D-hexosaminidase, β-D-glucuronidase, hyaluronidase, sperm adhesion molecule 1 and klotho genes were measured in synovial fibroblasts and synovial membrane samples of patients with rheumatoid arthritis and osteoarthritis by real-time PCR. β-D-Glucuronidase, β-D-glucosaminidase and β-D-galactosaminidase activities were characterized using chromogenic or fluorogenic substrates. Synovial fibroblast-derived microvesicles were also tested for glycosidase activity.

Results According to our data, β-D-hexosaminidase, β-D-glucuronidase, and klotho are expressed in the synovial membrane. Hexosaminidase is the major glycosidase expressed within the joints, and it is primarily produced by synovial fibroblasts. HexA subunit gene, one of the two genes encoding for the alpha or the beta chains of hexosaminidase, was characterized by the strongest gene expression. It was followed by the expression of HexB subunit gene and the β-D-glucuronidase gene, while the expression of hyaluronidase-1 gene and the klotho gene was rather low in both synovial fibroblasts and synovial membrane samples. Tumor growth factor-β1 profoundly downregulated glycosidase expression in both rheumatoid arthritis and osteoarthritis derived synovial fibroblasts. In addition, expression of cartilage-degrading glycosidases was moderately downregulated by proinflammatory cytokines including TNFα, IL-1β and IL-17.

Conclusions According to our present data, glycosidases expressed by synovial membranes and synovial fibroblasts are under negative regulation by some locally expressed cytokines both in rheumatoid arthritis and osteoarthritis. This does not exclude the possibility that these enzymes may contribute significantly to cartilage degradation in both joint diseases if acting in collaboration with the differentially upregulated proteases to deplete cartilage in glycosaminoglycans.

DMEM: Dulbecco’s modified Eagle’s medium; FCS: fetal calf serum; GuaB: β-D-glucuronidase; HexA: hexosaminidase A subunit; HexB: hexosaminidase B subunit; Hyal: hyaluronidase 1; IL: interleukin; MMP: matrix metalloproteinase; MV: microvesicle; NAG: β-D-N-acetyl-glucosaminidase; NOC-18: (2Z)-1-(2-[(2-aminoethyl)-N-(2-aminoethyl) amino)diazene-1-ium-1,2-diolate diethylenetriamine; OA: osteoarthritis; PCR: polymerase chain reaction; RA: rheumatoid arthritis; RANTES: Regulated on Activation Normal T Cell Expressed and Secreted; RT: reverse transcriptase; SF: synovial fibroblast; SF: synovial fluid; SM: synovial membrane; Spam1: sperm adhesion molecule 1; TGF-β1: tumor growth factor beta 1; TLR: Toll-like receptor; TNF: tumor necrosis factor.
Introduction
Rheumatoid arthritis (RA) is a chronic, progressive systemic autoimmune disease that affects approximately 1% of the adult population. Proinflammatory cytokines and chemokines are considered to be the key regulators, and certain proteases to be the major effector molecules, in the pathomechanism of the disease.

There has been a recent increasing awareness of the significance of post-translational protein modifications in health and disease. In rheumatology this is best exemplified by the significance of citrullination [1-3]. Even though glycosylation is the most frequent post-translational modification, its role is still poorly understood. Enzymes that collaborate to determine the final structures of glycans are glycosyl transferases and glycosidases. The significance of glycosidases has been recently suggested by studies in which glycosidase activity resulted in abrogation of arthritogenicity of IgG [4]. The current study focuses on glycosidases expressed locally, within the joints.

Earlier we found very low enzyme activities of α-D-mannosidase and β-D-galactosidase and β-D-glucuronidase activity in serum and synovial fluid (SFI) of patients with RA and osteoarthritis (OA). On the contrary, SFI exoglycosidases (β-D-N-acetyl-glucosaminidase (NAG) and β-D-glucuronidase (GusB)) were characterized by significantly elevated enzyme activities in patients with RA as compared with OA [5]. The NAG and GusB enzymes alone or in combination with matrix metalloproteinases (MMPs) were efficient in degrading hyaline cartilage directly [5]. The measured NAG activity is characteristic for hexosaminidase, the enzyme responsible for the hydrolysis of terminal nonreducing N-acetyl-D-hexosamine.

Until recently, β-D-glucuronidase activity was attributed solely to the lysosomal GusB enzyme. The anti-ageing klotho protein, however, was also shown to have β-D-glucuronidase activity [6]. Until now no study had investigated the expression of the klotho gene in synovial fibroblasts (SFs) and synovial membranes (SMs), and neither were any data available on the expression of the hyaluronidase 1 (Hyal1) and sperm adhesion molecule 1 (Spam1) hyaluronidase genes in the joints.

We also extended this work to the glycosidase-like Hc-gp 39 that we discovered earlier as one of the most abundant proteins synthesized by SFs [7]. Hc-gp 39 is classified as a member of the chitinase-like family 18 of proteins because of its amino acid sequence, although no glycohydrolase activity of this molecule has so far been demonstrated [8].

Cell-derived membrane-bound microvesicles (MVs) have also been shown to play an important role in mediating cell – cell communication and in the pathogenesis of several autoimmune diseases [9-13]. Lymphocyte-derived microvesicles activate SFs in a dose-dependent manner to release MMPs, proinflammatory cytokines and chemokines [13].

There is increasing evidence that SFs are key players in the pathogenesis of RA by invading and eroding hyaline cartilage. SFs, activated locally, produce a variety of cytokines, chemokines and matrix-degrading enzymes [14].

In the present work we investigated the effect of paramount cytokines including TNFα IL-1β, IL-17, tumor growth factor beta 1 (TGF-β1) and we also studied MVs as potential sources of glycosidases.

The current study describes for the first time the glycosidase expression profile of SFs in RA and OA, and demonstrates that glycosidases are under negative regulation in SFs.

Materials and methods

Patients
SFI samples were obtained from the knee joints of 31 patients (six males, 25 females) with RA and of 16 patients (four males, 12 females) with OA treated in the Hospital of Hospitaller Brothers of St John of God, Budapest, Hungary. All the patients suffered from exudative synovitis.

SMs were obtained at joint replacement surgery (in the Hospital of Hospitaller Brothers of St John of God, Budapest and the Department of Orthopedics, University Medical School of Szeged, Hungary) from 10 RA patients (one male, nine females; mean ± standard error mean (range) age, 61.5 ± 10.3 (25 to 79) years) and from 17 OA patients (seven males, 10 females; age, 64.53 ± 7.32 (39 to 79) years). All RA and OA patients met the American College of Rheumatology criteria for RA [15] and for OA [16], respectively.

RA patients were characterized by an erythrocyte sedimentation rate (mean ± standard error mean) of 28.60 ± 18.04 mm/hour, as opposed to 19.00 ± 9.88 mm/hour for patients with OA. The mean C-reactive protein level of RA patients was 22.16 ± 18.85 mg/l, but the C-reactive protein values of OA patients were not determined. The white blood cell count of patients with RA was 8,020 ± 1,360/μl, as compared with 7,019 ± 1,320/μl for patients with OA. The mean ± standard error mean (range) disease duration from diagnosis of RA patients was 10.4 ± 8.4 (0 to 35) years, as compared with 3.5 ± 2.25 (1 to 10) years for OA patients. Medication of RA patients included per os methotrexate, methylprednisolone and sulphasalazine.

The study was approved by the Human Investigation Review Board of the University of Szeged and all patients signed an informed consent form.

Isolation and culture of synovial fibroblasts
SFs were obtained by enzymatic digestion as described by Neidhart and colleagues [17]. Cells were grown in DMEM (Sigma-Aldrich Corp, St. Louis, MO, USA) with 10% FCS (GibcoBRL, Frederick, MD, USA). SFs were cultured for six to
eight passages. The cell viability was higher than 95% in all experiments. We found that the repeated passages ensured the purity of fibroblast cell populations without contaminating macrophages, as demonstrated by the lack of staining for CD68 (anti-human CD68-FITC; eBioscience Inc, San Diego, CA, USA). To rule out the possibility that SFs might have changed their native expression profile, we tested baseline glycosidase expression at every second passage, and did not find significant alterations from the P1 to P9 passages either in OA or RA SFs (see Additional data file 1). Gene expression pattern of RA samples may also vary depending on the disease stage. We did not, however, test synovial tissue samples from patients with early-stage RA in the present study.

Quantitative RT-PCR
Total RNA was extracted from SFs and SMs using the RNeasy® Mini Kit (Qiagen USA, Valencia, CA, USA). Relative quantification of hexosaminidase A subunit (HexA), hexosaminidase B subunit (HexB), Gusb, Hya1, Hc-gp 39, klotho, Spam1, MMP1 and MMP3 mRNAs (referred to mRNA of hypoxanthine phosphoribosyl transferase) was performed with TaqMan quantitative-PCR assays (Hs00166843_m1, Hs00166864_m1, Hs99999908_m1, Hs00537920_g1, Hs00609691_m1, Hs00183100_m1, Hs01095939_m1, Hs00899658_m1 and Hs00233962_m1 referred to Hs99999909_m1, respectively) on an ABI PRISM 7000 Sequence Detector (Applied Biosystems, Foster City, CA, USA) using standard protocols [18].

Enzyme assays
SMs were homogenized in a Heidolph Diax-type homogenizer on ice in buffer containing 0.2 M phenylmethylanesulphonylfluoride, 1 mg/ml PepstatinA, 0.2 M lodoacetamid, 0.2 M ethylenediamine tetraacetic acid (all purchased from Sigma-Aldrich). SFs were lysed with five freeze–thaw cycles. Enzyme activities were normalized to protein content (50 μg protein was used from all samples) measured by a standard Bradford protein assay. Enzyme activities were measured as described previously [5] and were expressed as units, determined using enzymes with known activities: GUS (EC 3.2.1.31) and NAG (EC 3.2.1.52) (all from Sigma-Aldrich).

Effect of cytokines on expression and secretion of glycosidases by synovial fibroblasts
SFs were cultured in the presence of human TNFα (BD Biosciences Pharmingen, San Jose, CA, USA), IL-1β and TGF-β1 (both from ImmunoTools, Friesoythe, Germany) in 0, 1, 10 and 50 ng/ml concentrations, and of IL-17 (ImmunoTools) in 0, 1, 10 and 100 ng/ml concentrations for 24 hours. The nitric oxide donor (2-)(1-(2-(aminoethyl)-N-(2-ammonioethyl) diamine-1-ium-1,2-diolate diethylentriamine (NOC-18) (Molecular Probes, Inc., Eugene, OR, USA) was used in 100 and 1,000 μM concentrations. For enzyme release assays, 5 × 10^4 cells were cultured in 96-well plates in phenol-red-free-RPMI without FCS in the presence of human TGF-β1, for 24 hours. The enzyme activity of both the supernatants and the cell lysates was determined as described above.

Enzyme histochemistry
SFs were plated onto chamber slides (Nunc Inc., Naperville, IL, USA) and were cultured for 24 hours. Cells were incubated with either 50 μM ImaGene Green C12FDGlcU β-d-glucuronidase or ELF® 97 N-acetylglucosaminidase substrates (both from Molecular Probes). The slides were analyzed in a Bio-Rad MRC 1024 confocal laser scanning microscope equipped with a krypton/argon mixed gas laser as the light source (Bio-Rad, Richmond, CA, USA).

Flow cytometric analysis of synovial fibroblast-derived microvesicles
The SFs were plated at 3 × 10^6 cells/75 cm^2 flasks in serum-free DMEM. After 24 hours the cell culture supernatants were collected and the spontaneously released MVs were tested immediately. First the supernatant was centrifuged at 500 × g for 10 minutes to remove cells, and was then incubated either with 50 μM ImaGene Green C12FDGlcU (the fluorogenic lipophilic substrate of β-d-glucuronidase) or ELF® 97 N-acetylglucosaminidase substrate (both from Molecular Probes) for 30 minutes. To verify the specificity of the reaction, D-glucaric acid-1,4-lactone, a β-d-glucuronidase inhibitor, was used (Molecular Probes). The number of stained MVs was determined by measuring the events for 30 seconds by a FACSCalibur (Beckton Dickinson & Co., San Jose, CA, USA) flow cytometer.

Electron microscopy of synovial fibroblast-derived microvesicles
SF 24-hour supernatants were centrifuged at 500 × g for 10 minutes, and were submitted to ultracentrifugation at 100,000 × g for 30 minutes. The pellet was fixed with 2% paraformaldehyde/2% glutaraldehyde for 2 hours, postfixed in 1% OsO4 for 30 minutes. The MVs were dehydrated in graded ethanol, block-stained with 2% uranyl acetate in 70% ethanol for 1 hour, and embedded in Taab 812 (Emmer Green, Reading, UK). Ultrathin sections were examined in a Hitachi 7100 transmission electron microscope (Hitachi, Tokyo, Japan).

Statistical analysis
Statistical analysis was performed using STATISTICA 7.1 (StatSoft Inc. Tulsa, OK, USA).

The Mann–Whitney rank sum test was performed for nonrelated samples and the paired t test was used for cytokine-treated samples (after a normality test was passed).

Results
Gene expression analysis
First, we analyzed the gene expression of glycosidases including HexA, HexB, Gusb, Hya1, klotho and Hc-gp39 by quanti-
Gene expressions were characterized in SFs and in SMs from RA patients and OA patients.

Gene expression of Hc-gp 39 was orders of magnitude higher than that of any of the other tested genes (Figure 1). We have found about 10-fold higher expression of Hc-gp 39 in SFs as compared with SM samples.

HexA and HexB genes were characterized by the second strongest gene expression in all samples (Figure 1). The expression of HexA gene was approximately the same both in SFs and in SMs. In contrast, we observed a significantly higher expression of HexB gene in RA and OA SFs as compared with the SMs. The expression of HexA gene has a tendency to be higher than that of HexB in SFs of RA fibroblasts. In SM samples, however, the dominance of HexA gene expression over HexB was highly significant.

The expression of GusB, Hyal1 and klotho showed a decreasing sequence of order, as shown in Figure 2. We observed significantly lower expression of these three genes in RA and OA SFs as compared with that in the RA and OA SMs. In OA SMs we found significantly higher Hyal1 expression as compared with the RA SMs. The expression of Spam1 gene was undetectable in any of the samples.

Enzyme assays
Enzyme activities were measured in SFs, SMs and SFls using chromogenic substrates of NAG, β-D-N-acetyl-galactosaminidase and β-D-glucuronidase. The data are summarized in Figure 3.

Activities of NAG, β-D-N-acetyl-galactosaminidase and GusB in RA SFs were significantly higher than in OA SFs. The activities of these enzymes in the SFs, however, were markedly lower, quite uniformly, than those detected in the homogenates of either the SMs or the SFs (Figure 3a to 3c). The activity of NAG in RA SFs was significantly higher than in RA SMs. In contrast, the activity of GusB in SFs was lower than in SMs. There was no significant difference in the GusB activities associated with the SM and SF of OA and RA patients (Figure 3a to 3c).

Detection of GusB and NAG in synovial fibroblasts using lipophilic fluorogenetic substrates
RA and OA SF monolayers were stained for GusB and NAG using fluorogenetic substrates. Both enzymes are localized to the lysosomes. The intensity of GusB substrate fluorescence was stronger in OA fibroblasts as compared with those isolated from patients with RA (Figure 4). The NAG substrate fluorescence intensity was much higher than that of the β-D-glucuronidase. The NAG staining was more intense in RA fibroblasts as compared with those isolated from OA patients (Figure 4).
GusB, Hyal1 and klotho gene expression in arthritis patients’ synovial membrane and fibroblast samples

Gene expression for β-D-glucuronidase (GusB), hyaluronidase 1 (Hyal1), and klotho genes was lower in rheumatoid arthritis (RA) and osteoarthritis (OA) synovial fibroblasts (SFs) than in RA and OA synovial membrane (SM) tissue samples (Mann-Whitney rank sum test). The expression of Hyal1 gene was significantly higher in OA SM as compared with RA SM (Mann-Whitney rank sum test). The expression of sperm adhesion molecule 1 gene was undetectable. Gex, gene expression; HGPRT, hypoxanthine phosphoribosyl transferase. *P < 0.05; **P < 0.01; ***P < 0.001.

Effect of cytokines and nitric oxide on expression and secretion of glycosidases by synovial fibroblasts

We tested the effect of various cytokines and nitric oxide on the gene expression of glycosidases. Relative gene expression (referred to hypoxanthine phosphoribosyl transferase) was determined by quantitative PCR. The relative gene expression in the unstimulated cells for each gene was defined as 100%.

As shown in Figures 5a and 6a, TGF-β1, has significantly downregulated the expression of HexA and HexB genes, as well as of GusB and Hc-gp 39. The suppression of gene expression was more pronounced in RA than OA samples (Figures 5a and 6a), and the strongest dose-dependent downregulation was observed in the case of Hc-gp 39 gene. TNFα downregulated the expression of Hc-gp-39, HexB and GusB in RA (Figure 5b), and the expression of HexA gene in OA (Figure 6b). IL-1β significantly decreased the expression of HexA, HexB and GusB in RA (Figure 5c), while it had no effect on gene expression in OA (Figure 6c). The next cytokine tested was IL-17. As shown in Figures 5d and 6d, stimulation of cells by IL-17 in RA decreased the gene expression of both HexB and GusB, whereas in OA it did not have an effect. Finally, we were interested in whether gene expression of the glycosidases was influenced by nitric oxide. In the presence of NOC-18 there was no change in the gene expression, except for Hc-gp 39 being downregulated in OA (Figures 5e and 6e). The expression of Hyal1 was significantly downregulated by TGF-β1 (50 ng/ml) and by IL-17 (10 ng/ml) in patients with RA. The gene expression of Hyal1 was very low, however, in all experiments (data not shown).

As a positive control for our assays, we also tested the expression of MMP1 and MMP3 upon stimulation by various cytokines. In all RA SFs, the cytokine-induced upregulation of gene expression of MMP3 was higher than fourfold. NOC-18 did not, however, induce changes in the MMP expression (data not shown).

Since the influence of cytokines on gene expression was minor with the exception of TGF-β1, we measured whether TGF-β1 treatment had an effect on NAG or GusB activities in both SF lysates and in the SF supernatants. We found that most NAG activity was detected inside the cells (Figure 7a) and showed no significant changes under the effect of TGFβ1 either in the cell lysates or in the supernatant (Figures 7a, b). In contrast, minimal GusB activity was found to be associated with SFs and most GusB activity was found in the 24-hour supernatant of the cells (Figure 7c, d).

Although we did not detect any change in GusB activity in SF lysates, 50 ng/ml TGF-β1 treatment resulted in a significant decrease of secreted enzyme activity in the supernatant (Figure 7d).
Enzyme-histochemical detection of glycosidases in synovial fibroblast cells. Enzyme-histochemical staining of rheumatoid arthritis (RA) and osteoarthritis (OA) synovial fibroblast monolayers for $\beta$-D-glucuronidase (GusB) and $\beta$-D-N-acetyl-glucosaminidase (NAG) using fluorogenic substrates. Nuclear areas show no fluorescent staining.

Detection of synovial fibroblast-derived microvesicles and microvesicle-associated GusB activity

To determine whether predominant glycosidases of SFs were also present in MVs, we tested the GusB and NAG activity associated with MVs in SF supernatants, SFl and serum samples of RA and OA patients using a lipophilic fluorogenic substrate. While we could not detect GusB activity associated with SFl-derived and serum-derived MVs, GusB activity was found to be associated with MVs in the supernatants of SFS of both RA and OA patients (Figure 8). The OA SF-derived MVs showed stronger GusB activity as compared with SF-derived MVs from RA patients. We could not detect NAG activity in synovial fibroblast-derived MVs using the fluorogenic NAG substrate.

Discussion

While numerous studies have characterized the role of fibroblast-derived proteases in cartilage destruction [19-23], during the past decades surprisingly little attention has been paid to the activity of glycosidases in rheumatology. The few studies from the 1970s that reported elevated levels of glycosidases in joint diseases [24-26] were hardly followed by reports on glycosidases until recently. We earlier demonstrated the ability of exoglycosidases to degrade hyaline cartilage [5]. Popko and colleagues [27-31] and Shikhman and colleagues [32] reported high hexosaminidase activity in the joints of patients with rheumatologic diseases, and Li and colleagues have
Gene expression of synovial fibroblast samples from rheumatoid arthritis patients after cytokine and NOC-18 treatment. Synovial fibroblasts (SFs) from patients with rheumatoid arthritis (RA) were cultured in the presence or absence of various cytokines or the nitric oxide donor \((\text{Z})-1-(2-(2-	ext{aminoethyl})-\text{N}=(2-	ext{ammonioethyl})\text{amino})\text{diazen-1-ium-1,2}-\text{dilolate diethyleneetriamine} \) (NOC-18) for 24 hours. Relative gene expression (referred to hypoxanthine phosphoribosyl transferase) was determined by realtime PCR. The relative gene expression in the unstimulated cells for each gene is defined as 100%. (a) Tumor growth factor beta 1 (TGF-β) stimulation (n = 4). (b) TNFα stimulation (n = 6). (c) IL-1β stimulation (n = 4). (d) IL-17 stimulation (n = 4). (e) NOC-18 stimulation (n = 3). Data shown as mean ± standard error mean. *P < 0.05, **P < 0.01, ***P < 0.0015 (paired t test).

GusB, β-D-glucuronidase; HexA, hexosaminidase A subunit; HexB, hexosaminidase B subunit.
recently shown an increased heparanase activity in RA SFs and tissue [33]. The synovial glycosidase gene expression pattern has not yet been described, however, and it also remained unclear whether the gene expression of glycosidases in SFs was regulated by inflammatory cytokines.

We found a robust gene expression of the glycosidase-like Hc-gp 39 in the SMs, and in particular in SFs, of both RA and OA patients. The strikingly elevated Hc-gp 39 expression in SFs as compared with the SMs may be explained either by inhibition of its expression within the synovium or by upregulation of it by factors during *in vitro* growth of fibroblasts.

Gene expression of synovial fibroblast samples from osteoarthritis patients after cytokine and NOC-18 treatment. Synovial fibroblasts (SFs) from patients with osteoarthritis (OA) were cultured in the presence or absence of various cytokines or the nitric oxide donor (2-(2-(2-aminoethyl)-N-(2-ammonioethyl) amino)diazene-1-ium-1,2-diolate diethylenetriamine (NOC-18) for 24 hours. Relative gene expression (referred to hypoxanthine phosphoribosyl transferase) was determined by real-time PCR. The relative gene expression in the unstimulated cells for each gene is defined as 100%.

(a) Tumor growth factor beta 1 (TGF-β1) stimulation (*n* = 6). (b) TNF-α stimulation (*n* = 6). (c) IL-1β stimulation (*n* = 3). (d) IL-17 stimulation (*n* = 3). (e) NOC-18 stimulation (*n* = 3). Data shown as mean ± standard error mean. *P < 0.05, **P < 0.01, ***P < 0.0015 (paired *t* test). GusB, β-D-glucuronidase; HexA, hexosaminidase A subunit; HexB, hexosaminidase B subunit.
According to our data, hexosaminidase is the glycosidase with the highest expression and activity in the joints. This is in accordance with the findings of previous studies [29].

In the present study we show that SFs appear to be major sources of this enzyme in the SMs as they are characterized by strong expression of both HexA and HexB genes. Hexosaminidase A is composed of both alpha and beta chains, whereas hexosaminidase B is a homodimer of beta chains. The rare hexosaminidase S isoenzyme is composed from HexA – HexA gene products [34,35]. In this work we found a significantly higher expression of HexA compared with HexB in SFs and SM samples. This raises the intriguing possibility of intraarticular expression of the rare hexosaminidase S, responsible for degradation of sulfated glycosaminoglycans [36].

We hypothesize that even though SFs show relatively low expression of GusB, they might accumulate significant amounts of this lysosomal enzyme – some of which might be released by cell-derived MVs. This concept is supported by the GusB activity detected in cell lysates that was comparable with that detected in SM homogenates, and also by its association with cell-derived MVs.

The association of GusB activity with SF-derived MVs sheds light on a previously unrecognized localization of this enzyme.

Innate immunity plays a key role in the initiation of an immune response. Its germline encoded receptors such as Toll-like receptors (TLRs) detect danger signals. Functional TLR2 was reported in SFs of patients who had RA [37,38]. RA SFs, activated via TLR2, were suggested to contribute to arthritis development by secretion of chemokines. While exogenous TLR ligands have been investigated extensively, only few endogenous TLR ligands have so far been identified. These ligands include carbohydrate degradation products of the extracellular matrix (tetrasaccharides and hexasaccharides of hyaluronate and heparan sulphate) [39-41]. Interestingly, all known carbohydrate TLR ligands fall into the category of oligosaccharides generated by endoglycosidases, enzymes that...
cleave polysaccharide chains between nonterminal residues. The endoglycosidases that we have tested in the present study (Hyal1 and Spam1) showed minimal activity within the joints. Based on our results, therefore, it seems very likely that the carbohydrate degradation product ligands for TLRs are generated by exogenous (for example, microbial) endoglycosidases rather than SM-derived or SF-derived enzymes.

In line with earlier data, we found that hexosaminidase was the dominant exoglycosidase in the joints. Constitutive generation of cleavage products such as glucosamine by hexosaminidase may be part of the normal extracellular matrix/glycosaminoglycan turnover. Glucosamine has been recently shown to globally protect chondrocytes from the arthritogenic effects of IL-1β (by blocking the response in ~73% of IL-1β-stimulated genes) [42]. Glucosamine might therefore act primarily as an endogenous anti-inflammatory molecule within the joints. Under physiological conditions, hexosaminidase cleavage products may thus play a protective role and maintain tissue homeostasis, while this homeostatic balance may be shifted during microbial infections. In acute inflammation, frustrated phagocytosis and elevated intracellular free calcium level-induced secretion of lysosomal resident enzymes may result in significant release of further exoglycosidases by infiltrating cells (for example, monocytes and neutrophil granulocytes) [43] that might act in concert with SF-derived hexosaminidase. Upon the alternating action of certain exoglycosidases (hexosaminidase and glucuronidase), cartilage matrix degradation may dominate and lead to the release of glycosaminoglycans from the extracellular matrix.

One of the most striking findings of our study was that the regulation of gene expression of glycosidases and proteases by cytokines seems to be discordant. In sharp contrast to MMPs and other proteases, such as certain cathepsins – which have been reported to be highly inducible by proinflammatory
cytokines [44-47] – we found that glycosidases were moderately downregulated by proinflammatory cytokines IL-1β, IL-17 and TNFα. The most pronounced cytokine effect was seen in the case of TGF-β1, which profoundly downregulated glycosidase expression in both RA and OA fibroblasts.

Transforming growth factor beta is found abundantly in the SM [48], and constitutive upregulation of the transforming growth factor beta pathway has been shown in RA SFs [49]. Transforming growth factor beta exerts both anti-inflammatory and proinflammatory actions, as exemplified by its ability to downregulate RANTES expression and by stimulating the synthesis of MMP-1 and IL-1 [50].

We hypothesize that the relatively stable expression and tight regulation control of synovial glycosidases are critical factors in the joints. Numerous cytokines exert complex regulatory mechanisms in RA. Our observation that glycosidases appear to be under negative control and are downregulated rather than stimulated by inflammatory cytokines may suggest that an enhanced expression of these enzymes could lead to severe and unforeseeable consequences. The extracellular matrix has been reported to serve as a repository of transforming growth factor beta and other growth factors of which the release is regulated via degradation of proteoglycans [51]. The long list of glycosaminoglycan binding proteins includes growth factors (like fibroblast growth factors, vascular endothelial growth factor, insulin-like growth factor-binding proteins), morphogens, enzymes, numerous cytokines and chemokines, interleukins, and so forth [52]. It can be hypothesized that a stringent control of the gene expression of glycosidases may prevent the synchronized release of the plethora of tissue-bound proteins.

Until recently, GusB has been regarded as a housekeeping gene in humans due to the absence of TATA box and high G+C contents within its putative promoter sequence [53]. Downregulation of GusB expression was demonstrated recently by the calcium ionophore A23187, the calcium ATPase inhibitor thapsigargin as well as by the calcium channel blocker verapamil in the human hepatoma cell line HepG2 [54]. The present study provides the first evidence that glycosidase gene expression (including the one of GusB) is regulated by human cytokines.

Conclusions

Our data drive attention to the dominant negative regulation of a functional group of genes – glycosidases – by paramount cytokines in SFs that differs remarkably from regulation of proteases. The fact that we did not find significant differences between patients with RA and OA with respect to their glycosidase gene expression suggests a similar role and regulation for exoglycosidases in the two diseases. This hypothesis does not contradict these enzymes contributing significantly to cartilage degradation in both joint diseases if acting in concert with MMPs to deplete cartilage in glycosaminoglycans. Our data suggest that the earlier reported elevated glycosidase activities in RA joints were probably not due to enhanced gene expression of resident SFs, but rather resulted from enzyme release by cells (including infiltrating inflammatory cells) within the joints.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

MP, GN, PN, AF and EIB participated in the design of the study. Experiments were performed by MP, PP, MCH, AK, KP and MM. GN, PG, TL, KT and KW contributed by providing human samples. Analysis of data was carried out by MP, GN, BG, AF and EIB. Intellectual contributions to the manuscript were provided by MP, GN, PG, TL, KT, KW, AF and EIB. All authors read and approved the final manuscript.

Additional files

The following Additional files are available online:

Additional data file 1

An image file containing a figure demonstrating baseline glycosidase expression of SFs during passaging. The baseline glycosidase expression of SFs was tested at every second passage. There was no significant alteration of glycosidase gene expression from P1 to P9 passages either in OA (n = 6) or RA SFs (n = 5). See http://www.biomedcentral.com/content/supplementary/ar2697-S1.jpeg

Acknowledgements

The present work was supported by research grants OTKA T046468, OTKA F61030, OTKA 74247 and OTKA 77537 and the research training grant MRTN-CT-2005-019581. GN is a Bolyai Research Fellow.

References

1. Ménard HA: Anti-CCP versus anti-Sa antibodies for the diagnosis of RA. Nat Clin Pract Rheumatol 2007, 3:76-77.
2. Avouac J, Gossec L, Dougdados M: Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2006, 65:845-851.
3. György B, Tóth E, Tarcsa E, Falus A, Buzás EI: Citrullination: a posttranslational modification in health and disease. Int J Biochem Cell Biol 2006, 38:1662-1677.
4. Nandakumar KS, Collin M, Olsén A, Nimmerjahn F, Blom AM, Ravetch JV, Holmdahl R: Endoglycosidase treatment abrogates IgG arthritogenicity: importance of IgG glycosylation in arthritis. Eur J Immunol 2007, 37:2973-2982.
5. Ortuzy Z, Polgar A, Gomor B, Geher P, Lakatos T, Giant TT, Gay RE, Gay S, Pällinger E, Farkas C, Farkas E, Tóthfalusi L, Kocsis K, Falus A, Buzás EI: Synovial fluid exoglycosidases are predictors of rheumatoid arthritis and are effective in cartilage glycosaminoglycan depletion. Arthritis Rheum 2003, 48:2163-2172.
6. Torres PU, Prie D, Molina-Blétry V, Beck L, Silve C, Friedlander G: Klotho: an antiaging protein involved in mineral and vitamin D metabolism. Kidney Int 2007, 71:730-737.

7. Nyrkös P, Golds EE: Human synovial cells secrete a 39 kDa protein similar to a bovine mammary protein expressed during the non-lactating period. Biochem J 1990, 268:265-268.

8. Fusetti F, Fliging T, Kalk KH, Bos E, Dijkstra BW: Crystal structure and carbohydrate-binding properties of the human cartilage glycoprotein-39. J Biol Chem 2003, 278:37753-37760.

9. Distler JH, Piseyski DS, Huber LC, Kalden JR, Gay S, Distler O: Microparticles as regulators of inflammation: novel players of cellular crosstalk in the rheumatic diseases. Arthritis Rheum 2005, 52:3337-3348.

10. Distler JH, Huber LC, Gay S, Distler O, Piseyski DS: Microparticles as mediators of cellular cross-talk in inflammatory disease. Autoimmunity 2006, 39:683-690.

11. Distler JH, Jünger A, Huber LC, Seemayer CA, Reich CF 3rd, Gay RE, Michel BA, Fontana A, Gay S, Piseyski DS, Distler O: The induction of MMP-1, metzincinproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles. Proc Natl Acad Sci USA 2005, 102:2892-2897.

12. Huber LC, Distler O, Tarnier I, Gay RE, Gay S, Pap T: Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology 2006, 45:669-673.

13. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA Jr, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Webb J: The American College of Rheumatology 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.

14. Altman R, Alarcon G, Appelrouth D, Bloch D, Borenstein D, Brandt KD, Mitchell H, Neustadt DH, Pinals RS, Schaller JG, Sharief JS, Wilder RL, Hunder GG: The American Rheumatism Association 1988 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.

15. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA Jr, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharief JS, Wilder RL, Hunder GG: The American Rheumatism Association 1988 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.

16. Altman R, Alarcon G, Appelrouth D, Bloch D, Borenstein D, Brandt K, Brown C, Cooke TD, Daniel W, Feldman D, Greenwald R, Hochberg M, Howell D, Ike R, Kapila P, Kappel D, Koopman W, Marino C, McDonald E, McShane DJ: The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum 1991, 34:505-514.

17. Neidhart M, Gay RE, Gay S: Anti-interleukin-1 and anti-CD44 immunoregulatory producing significant inhibition of cartilage destruction in an in vitro model of cartilage invasion by rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2000, 43:1719-1728.

18. Koncz A, Pasztói M, Mazan M, Fazakas F, Buzas E, Falus A, Nagy CA: Nitric oxide intermediates T cell cytokine production and signal transduction in histidine decarboxylase knockout mice. J Immunol 2007, 179:6613-6619.

19. Little CB, Hughes CE, Curtis CL, Janusz MJ, Bohne R, Wang-Wei-gan S, Taiwo YO, Mitchell PG, Otterness IG, Flannery CR, Cater-sen B: Matrix metalloproteinases are involved in C-terminal and interglobular domain processing of cartilage aggrecan in late stage cartilage degradation. Matrix Biol 2002, 21:271-288.

20. Burrage PS, Mix KS, Brinkerhoff CE: Matrix metalloproteinases: role in arthritis. Front Biosci 2006, 11:292-543.

21. Emokpok P, Nadis DG: The ADAM gene family: microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007, 9:654-659.

22. Distler JH, Jünger A, Huber LC, Seemayer CA, Reich CF 3rd, Gay RE, Michel BA, Fontana A, Gay S, Piseyski DS, Distler O: The induction of MMP-1, metzincinproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles. Proc Natl Acad Sci USA 2005, 102:2892-2897.

23. Distler JH, Piseyski DS, Huber LC, Kalden JR, Gay S, Distler O: Microparticles as regulators of inflammation: novel players of cellular crosstalk in the rheumatic diseases. Arthritis Rheum 2005, 52:3337-3348.

24. Distler JH, Huber LC, Gay S, Distler O, Piseyski DS: Microparticles as mediators of cellular cross-talk in inflammatory disease. Autoimmunity 2006, 39:683-690.

25. Distler JH, Jünger A, Huber LC, Seemayer CA, Reich CF 3rd, Gay RE, Michel BA, Fontana A, Gay S, Piseyski DS, Distler O: The induction of MMP-1, metzincinproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles. Proc Natl Acad Sci USA 2005, 102:2892-2897.

26. Ganguly NK, Kiningham JG, Lloyd B, Lloyd RS, Price CP, Triger DR, Wright R: Acid hydrolases in monocytes from patients with inflammatory bowel disease, chronic liver disease, and rheumatoid arthritis. Lancet 1978, 1:1073-1075.

27. Popko J, Zalewska A, Olszewski S, Górska A, Sierakoowski S, Zwi-ker Z, Urban M: Activity of N-acetyl-beta-hexosaminidase in serum and joint fluid of the knees of patients with juvenile idi-opathic arthritis. Clin Exp Rheumatol 2003, 21:87-95.

28. Popko J, Zalewska A, Golaszew ska Z, Marciniak J, Sierakoowski S, Worowski K, Zwi ker K: Comparative analysis of hexosamin- idase and cathepin D expression in synovial fluid of patients with rheumatoid arthritis and traumatized joints. Clin Exp Rheumatol 2005, 23:725-726.

29. Popko J, Marciniak J, Zalewska A, Maldyk P, Rogalski M, Zwi ker K: The activity of exoglycosidases in the synovial membrane and knee fluid of patients with rheumatoid arthritis and juvenile idio-pathic arthritis. Arthritis Rheum 2005, 52:190-202.

30. Popko J, Marciniak J, Zalewska A, Maldyk P, Rogalski M, Zwi ker K: The activity of exoglycosidases in the synovial membrane and knee fluid of patients with rheumatoid arthritis and juvenile idi-opathic arthritis. Arthritis Rheum 2005, 52:190-202.

31. Popko J, Marciniak J, Zalewska A, Maldyk P, Rogalski M, Zwi ker K: The activity of exoglycosidases in the synovial membrane and knee fluid of patients with rheumatoid arthritis and juvenile idio-pathic arthritis. Arthritis Rheum 2005, 52:190-202.

32. Popko J, Marciniak J, Zalewska A, Maldyk P, Rogalski M, Zwi ker K: The activity of exoglycosidases in the synovial membrane and knee fluid of patients with rheumatoid arthritis and juvenile idio-pathic arthritis. Arthritis Rheum 2005, 52:190-202.

33. Popko J, Marciniak J, Zalewska A, Maldyk P, Rogalski M, Zwi ker K: The activity of exoglycosidases in the synovial membrane and knee fluid of patients with rheumatoid arthritis and juvenile idio-pathic arthritis. Arthritis Rheum 2005, 52:190-202.

34. Popko J, Marciniak J, Zalewska A, Maldyk P, Rogalski M, Zwi ker K: The activity of exoglycosidases in the synovial membrane and knee fluid of patients with rheumatoid arthritis and juvenile idio-pathic arthritis. Arthritis Rheum 2005, 52:190-202.

35. Popko J, Marciniak J, Zalewska A, Maldyk P, Rogalski M, Zwi ker K: The activity of exoglycosidases in the synovial membrane and knee fluid of patients with rheumatoid arthritis and juvenile idio-pathic arthritis. Arthritis Rheum 2005, 52:190-202.

36. Popko J, Marciniak J, Zalewska A, Maldyk P, Rogalski M, Zwi ker K: The activity of exoglycosidases in the synovial membrane and knee fluid of patients with rheumatoid arthritis and juvenile idio-pathic arthritis. Arthritis Rheum 2005, 52:190-202.

37. Popko J, Marciniak J, Zalewska A, Maldyk P, Rogalski M, Zwi ker K: The activity of exoglycosidases in the synovial membrane and knee fluid of patients with rheumatoid arthritis and juvenile idio-pathic arthritis. Arthritis Rheum 2005, 52:190-202.
45. Fuchs S, Skwara A, Bloch M, Dankbar B: Differential induction and regulation of matrix metalloproteinases in osteoarthritic tissue and fluid synovial fibroblasts. Osteoarthritis Cartilage 2004, 12:409-418.

46. Kanangat S, Postlethwaite A, Hasty K, Kang A, Smeltzer M, Appling W, Schaberg D: Induction of multiple matrix metalloproteinases in human dermal and synovial fibroblasts by Staphylococcus aureus: implications in the pathogenesis of septic arthritis and other soft tissue infections. Arthritis Res Ther 2006, 8:R176.

47. Hou WS, Li W, Keyszer G, Weber E, Levy R, Klein MJ, Gravallese EM, Goldring SR, Brömme D: Comparison of cathepsins K and S expression within the rheumatoid and osteoarthritic synovium. Arthritis Rheum 2006, 46:663-674.

48. Taketazu F, Kato M, Gobl A, Ichijo H, ten Dijke P, Itoh J, Kyogoku M, Rönnelid J, Miyazono K, Heldin CH, Funa K: Enhanced expression of transforming growth factor-beta s and transforming growth factor-beta type II receptor in the synovial tissues of patients with rheumatoid arthritis. Lab Invest 1994, 70:620-630.

49. Pohlers D, Beyer A, Koczan D, Wilhelm T, Thiesen HJ, Kinne RW: Constitutive upregulation of the transforming growth factor-beta pathway in rheumatoid arthritis synovial fibroblasts. Arthritis Res Ther 2007, 9:R59.

50. Müller-Ladner U, Ospelt C, Gay S, Distler O, Pap T: Cells of the synovium in rheumatoid arthritis. Synovial fibroblasts. Arthritis Res Ther 2007, 9:223.

51. Imai K, Hiramatsu A, Fukushima D, Pierschbacher MD, Okada Y: Degradation of decorin by matrix metalloproteinases: identification of the cleavage sites, kinetic analyses and transforming growth factor-beta 1 release. Biochem J 1997, 322:809-814.

52. Esko JD, Linhardt RJ: Proteins that bind sulfated glycosaminoglycans. In Essentials of Glycobiology 2nd edition. Edited by: Varki A, Cummings D, Esko JD, Freeze HH, Stanley P, Bertozzi CR, Hart GW, Etzler ME; Plainview, NY: Cold Spring Harbor Laboratory Press; 2008:441-453.

53. Kunert-Keil C, Sporker B, Bien S, Wolf G, Grube M, Kroemer HK: Involvement of AP-2 binding sites in regulation of human β-glucuronidase. Naunyn Schmiedebergs Arch Pharmacol 2004, 370:331-339.

54. Grube M, Kunert-Keil C, Sporker B, Kroemer HK: Verapamil regulates activity and mRNA-expression of human β-glucuronidase in HepG2 cells. Naunyn Schmiedebergs Arch Pharmacol 2003, 368:463-469.